• 1
    Huitema A, Tibben M, Kerbusch T, et al. High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red blood cells. J Liq Chrom Rel Technol 2000;23:17251744.
  • 2
    Ren S, Kalhorn T, McDonald F, et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 1998;64:289301.
  • 3
    Xie H, Griskevicius L, Stahle L, et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharmaceut Sci 2006;27:5461.
  • 4
    McCune J, Salinger D, Vicini P, et al. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: A report from the children's oncology group. J Clin Pharmacol 2009;49:88102.
  • 5
    de Jonge M, van Dam S, Hillebrand M, et al. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N′,N″-triethylenethiophophoramide (thiotepa) and N,N′,N″-triethylenephosphoramide (tepa) in human plasma by high performance liquid chromatography couples with electrospray ionization tandem mass spectrometry. J Mass Spectrom 2004;39:262271.
  • 6
    Holford H. Pharmacokinetics and pharmacodynamics: Rational dosing and time course of drug action. In: KatzungB, MastersS, TrevorA, eds. Basic and Clinical Pharmacology, 11th ed. New York: McGraw-Hill Companies; 2009:3766.
  • 7
    Wang H, Tompkins L. CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 2008;9:598610.
  • 8
    Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004;50:22022210.
  • 9
    Nakajima M, Komagata S, Fujiki Y, et al. Genetic polymorphisms of CYP2B6 affects the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 2007;17:431445.
  • 10
    Vail D. Veterinary co-operative oncology group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194213.
  • 11
    Cros S, Theilen G, Madewell B, et al. Cyclophosphamide induced cystitis in the dog and cat. J Am Vet Med Assoc 1977;171:259262.
  • 12
    Petros W, Broadwater G, Berry D, et al. Association of high dose cyclophosphamide, cisplatin and carmustine pharmacokinetics with survival, toxicity and dosing weight in patients with primary breast cancer. Clin Cancer Res 2002;8:698705.
  • 13
    Frye R, Zgheib N, Matzke G, et al. Liver disease selectively modulates cytochrome P450 mediated metabolism. Clin Pharmacol Ther 2006;80:235245.
  • 14
    Struck R, Alberts D, Horne K, et al. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res 1987;47:27232726.
  • 15
    Ludeman S, Shulman-Roskes E, Wong K, et al. Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: Synthesis and deuterium labeling for applications to metabolite quantification. J Pharm Sci 1995;84:393398.
  • 16
    Charney S, Bergman P, Hohenhaus A, et al. Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990–1996). J Am Vet Med Assoc 2003;222:13881393.
  • 17
    Sladek N, Doeden D, Powers J, et al. Plasma concentrations of 4-hyroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 1984;68:12471254.
  • 18
    Petros W, Hopkins P, Spruill S, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics and overall survival in patients with breast cancer. J Clin Oncol 2005;23:61176125.
  • 19
    Timm R, Kaiser R, Lotsch J, et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenom J 2005;5:365373.
  • 20
    Salinger D, McCune J, Ren A, et al. Real time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: A Bayesian pharmacokinetic approach. Clin Cancer Res 2006;12:48884898.
  • 21
    Peterson J, Couto C, Hammer A, et al. Acute sterile hemorrhagic cystitis after a single administration of cyclophosphamide in 3 dogs. J Am Vet Med Assoc 1992;201:15721574.
  • 22
    Pinto N, Ludeman S, Dolan M. Pharmacogenetic studies related to cyclophosphamide based therapy. Pharmacogenomics 2009;10:18971903.
  • 23
    Hong P, Srigritsanapol A, Chan K. Pharmacokinetics of 4-hydroxcyclophosphamide and metabolites in the rat. Drug Metab Dispos 1989;19:17.
  • 24
    Chun R, Garrett L, Vail D. Cancer chemotherapy. In: WithrowS, VailD, eds. Withrow and MacEwen's Small Animal Clinical Oncology, 4th ed. London: Saunders; 2007:163193.